- Home
- CRVS vs NRC Comparison
CRVS vs NRC Comparison
Compare CRVS & NRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- NRC
- Stock Information
- Founded
- CRVS 2014
- NRC 1981
- Country
- CRVS United States
- NRC United States
- Employees
- CRVS N/A
- NRC N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- NRC Biotechnology: Commercial Physical & Biological Resarch
- Sector
- CRVS Health Care
- NRC Health Care
- Exchange
- CRVS Nasdaq
- NRC Nasdaq
- Market Cap
- CRVS 305.4M
- NRC 354.5M
- IPO Year
- CRVS 2016
- NRC N/A
- Fundamental
- Price
- CRVS $5.75
- NRC $14.65
- Analyst Decision
- CRVS Strong Buy
- NRC
- Analyst Count
- CRVS 4
- NRC 0
- Target Price
- CRVS $15.00
- NRC N/A
- AVG Volume (30 Days)
- CRVS 518.7K
- NRC 101.8K
- Earning Date
- CRVS 08-07-2025
- NRC 10-24-2025
- Dividend Yield
- CRVS N/A
- NRC 3.27%
- EPS Growth
- CRVS N/A
- NRC N/A
- EPS
- CRVS N/A
- NRC 0.77
- Revenue
- CRVS N/A
- NRC $140,314,000.00
- Revenue This Year
- CRVS N/A
- NRC N/A
- Revenue Next Year
- CRVS N/A
- NRC N/A
- P/E Ratio
- CRVS N/A
- NRC $19.08
- Revenue Growth
- CRVS N/A
- NRC N/A
- 52 Week Low
- CRVS $2.54
- NRC $9.76
- 52 Week High
- CRVS $10.00
- NRC $22.99
- Technical
- Relative Strength Index (RSI)
- CRVS 65.10
- NRC 47.80
- Support Level
- CRVS $5.28
- NRC $14.45
- Resistance Level
- CRVS $5.64
- NRC $15.60
- Average True Range (ATR)
- CRVS 0.30
- NRC 0.64
- MACD
- CRVS 0.03
- NRC -0.03
- Stochastic Oscillator
- CRVS 77.70
- NRC 17.05
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About NRC National Research Corporation (Delaware)
National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations. Its portfolio of solutions represents a set of capabilities that individually and collectively provide value to clients. It operates in the United States and Canada, of which key revenue is derived from the United States.